

chain nodes :

7 8 9 17 18 19 20 21

ring nodes :

1 2 3 4 5 6 10 11 12 13 14 15

chain bonds :

2-17 5-7 7-8 7-9 9-11 17-18 17-20 18-19 20-21

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 10-11 10-15 11-12 12-13 13-14 14-15

exact/norm bonds :

1-2 1-6 2-3 2-17 3-4 4-5 5-6 5-7 7-8 7-9 9-11 10-11 10-15  
11-12 12-13 13-14 14-15 18-19 20-21

exact bonds :

17-18 17-20

isolated ring systems :

containing 1 : 10 :

G1:O,N

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:CLASS  
10:Atom 11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 17:CLASS 18:CLASS  
19:Atom 20:CLASS 21:Atom

# STN Columbus

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America  
NEWS 2 "Ask CAS" for self-help around the clock  
NEWS 3 JUL 20 Powerful new interactive analysis and visualization software,  
STN AnaVist, now available  
NEWS 4 AUG 11 STN AnaVist workshops to be held in North America  
NEWS 5 AUG 30 CA/CAPLUS - Increased access to 19th century research documents  
NEWS 6 AUG 30 CASREACT - Enhanced with displayable reaction conditions  
NEWS 7 SEP 09 ACD predicted properties enhanced in REGISTRY/ZREGISTRY  
NEWS 8 SEP 22 MATHDI to be removed from STN

NEWS EXPRESS JUNE 13 CURRENT WINDOWS VERSION IS V8.0, CURRENT  
MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),  
AND CURRENT DISCOVER FILE IS DATED 13 JUNE 2005

NEWS HOURS STN Operating Hours Plus Help Desk Availability  
NEWS INTER General Internet Information  
NEWS LOGIN Welcome Banner and News Items  
NEWS PHONE Direct Dial and Telecommunication Network Access to STN  
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that  
specific topic.

All use of STN is subject to the provisions of the STN Customer  
agreement. Please note that this agreement limits use to scientific  
research. Use for software development or design or implementation  
of commercial gateways or other similar uses is prohibited and may  
result in loss of user privileges and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 11:11:58 ON 02 OCT 2005

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 11:12:20 ON 02 OCT 2005

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2005 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file  
provided by InfoChem.

STRUCTURE FILE UPDATES: 30 SEP 2005 HIGHEST RN 864353-93-5

DICTIONARY FILE UPDATES: 30 SEP 2005 HIGHEST RN 864353-93-5

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2005

Please note that search-term pricing does apply when  
conducting SmartSELECT searches.

\*\*\*\*\*

# STN Columbus

\*  
\* The CA roles and document type information have been removed from \*  
\* the IDE default display format and the ED field has been added, \*  
\* effective March 20, 2005. A new display format, IDERL, is now \*  
\* available and contains the CA role and document type information. \*  
\*  
\*\*\*\*\*

Structure search iteration limits have been increased. See HELP SLIMITS for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:  
<http://www.cas.org/ONLINE/DBSS/registryss.html>

=>  
Uploading structure

L1 STRUCTURE UPLOADED

=> s l1  
SAMPLE SEARCH INITIATED 11:19:04 FILE 'REGISTRY'  
SAMPLE SCREEN SEARCH COMPLETED - 135 TO ITERATE

100.0% PROCESSED 135 ITERATIONS 0 ANSWERS  
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*  
BATCH \*\*COMPLETE\*\*  
PROJECTED ITERATIONS: 2003 TO 3397  
PROJECTED ANSWERS: 0 TO 0

L2 0 SEA SSS SAM L1

=> s l1 sss full  
FULL SEARCH INITIATED 11:20:21 FILE 'REGISTRY'  
FULL SCREEN SEARCH COMPLETED - 2484 TO ITERATE

100.0% PROCESSED 2484 ITERATIONS 31 ANSWERS  
SEARCH TIME: 00.00.01

L3 31 SEA SSS FUL L1

=> file caplus  
COST IN U.S. DOLLARS SINCE FILE TOTAL  
ENTRY SESSION  
FULL ESTIMATED COST 166.92 167.13

FILE 'CAPLUS' ENTERED AT 11:20:28 ON 02 OCT 2005  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing

## STN Columbus

of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 2 Oct 2005 VOL 143 ISS 15

FILE LAST UPDATED: 30 Sep 2005 (20050930/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l3

L4 1 L3

=> d l4 bib abs hitstr

L4 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2005 ACS on STN

Full Text

AN 2004:453187 CAPLUS

DN 141:7141

TI A preparation of piperazine derivatives, useful as 17 $\beta$ -hydroxysteroid dehydrogenase type 3 inhibitors

IN Paruch, Kamil; Guzi, Timothy J.

PA Schering Corporation, USA

SO PCT Int. Appl., 49 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004046111	A1	20040603	WO 2003-US36203	20031114
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LU, LV, MA, MD, MG, MK, MN, MX, MZ, NI, NO, NZ, PG, PH, PL, PT, RO, RU, SC, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UZ, VC, VN, YU, ZA, ZM				
	RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2506290	AA	20040603	CA 2003-2506290	20031114
	US 2004127503	A1	20040701	US 2003-713828	20031114
	EP 1562901	A1	20050817	EP 2003-783382	20031114
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
PRAI	US 2002-427263P	P	20021118		
	WO 2003-US36203	W	20031114		
OS	MARPAT 141:7141				
GI					

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

AB The invention relates to a prepn. of piperazine derivs. of formula I [wherein: X is CH or N; Z is O or NH, N-alkyl, or N-aryl, etc.; R1 and R2 are independently selected from (un)substituted (hetero)aryl, (hetero)arylalkyl; R3 is H, OH, alkoxy, aryloxy, etc.; R4 is H, (cyclo)alkyl, (hetero)aryl, etc.; R5 is C(O)R6 or SO2R6; R6 is alkyl,

(hetero)aryl, (hetero)arylalkyl, (un)substituted amine], useful as inhibitors of type 3 17 $\beta$ -hydroxysteroid dehydrogenase. The invention compds. are claimed to be useful for the treatment, prevention, inhibition, or amelioration of diseases such as prostate cancer, acne, and androgenic alopecia, etc. The invention compds. exhibited a range of 17 $\beta$ -hydroxysteroid dehydrogenase type 3 binding activity from about 0.005 nM to 10 nM. For instance, piperazine deriv. II was prepd. via amination of phenyl(trifluoromethylphenyl)methanol by (S)-2-tert-butylpiperazine (example 7) and subsequent reaction of the obtained piperazine deriv. III and piperidine deriv. IV (example 15).

IT 696644-18-5P 696644-21-0P 696644-24-3P

696644-28-7P 696644-32-3P 696644-36-7P


RL: PAC (Pharmacological activity); PUR (Purification or recovery); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of 17 $\beta$ -hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen-dependent diseases)

RN 696644-18-5 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[[(2S)-2-(1,1-dimethylethyl)-4-[(S)-phenyl[4-(trifluoromethyl)phenyl]methyl]-1-piperazinyl]carbonyl]amino]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 696644-21-0 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[[(2S)-2-(1,1-dimethylethyl)-4-[(R)-phenyl[4-(trifluoromethyl)phenyl]methyl]-1-piperazinyl]carbonyl]amino]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 696644-24-3 CAPLUS

# STN Columbus

CN 1-Piperidinecarboxylic acid, 4-[[[(2S)-2-(1,1-dimethylethyl)-4-[(S)-phenyl[4-(trifluoromethoxy)phenyl]methyl]-1-piperazinyl]carbonyl]amino]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 696644-28-7 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[[(2S)-2-(1,1-dimethylethyl)-4-[(R)-phenyl[4-(trifluoromethoxy)phenyl]methyl]-1-piperazinyl]carbonyl]amino]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 696644-32-3 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[[(2S)-2-(1,1-dimethylethyl)-4-[(S)-[4-(1,1-dimethylethyl)phenyl]phenylmethyl]-1-piperazinyl]carbonyl]amino]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 696644-36-7 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[[(2S)-2-(1,1-dimethylethyl)-4-[(R)-[4-(1,1-dimethylethyl)phenyl]phenylmethyl]-1-piperazinyl]carbonyl]amino]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 696643-77-3P 696643-81-9P 696643-85-3P  
 696643-88-6P 696643-92-2P 696643-96-6P  
 696644-00-5P 696644-12-9P 696644-15-2P  
 696644-40-3P 696644-45-8P 696644-50-5P  
 696644-54-9P 696644-58-3P 696644-60-7P  
 696644-64-1P 696644-66-3P 696644-68-5P  
 696644-70-9P 696644-72-1P 696644-78-7P  
 696644-82-3P 696644-87-8P 696644-92-5P  
 696644-99-2P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of 17 $\beta$ -hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen-dependent diseases)

RN 696643-77-3 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[[(2S)-2-(1,1-dimethylethyl)-4-[phenyl[4-(trifluoromethyl)phenyl]methyl]-1-piperazinyl]carbonyl]amino]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 696643-81-9 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[[(2S)-4-(diphenylmethyl)-2-(1-methylethyl)-1-piperazinyl]carbonyl]amino]-, 1,1-dimethylethyl ester (9CI)  
(CA INDEX NAME)


Absolute stereochemistry.



RN 696643-85-3 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[[(2S)-4-[(4-chlorophenyl)phenylmethyl]-2-(1-methylethyl)-1-piperazinyl]carbonyl]amino]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 696643-88-6 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[[(2S)-2-(1,1-dimethylethyl)-4-[phenyl[4-(trifluoromethoxy)phenyl]methyl]-1-piperazinyl]carbonyl]amino]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 696643-92-2 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[[(2S)-2-(1,1-dimethylethyl)-4-[[4-(1,1-dimethylethyl)phenyl]phenylmethyl]-1-piperazinyl]carbonyl]amino]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 696643-96-6 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[[(2S)-4-[bis[4-(trifluoromethyl)phenyl]methyl]-2-(1,1-dimethylethyl)-1-piperazinyl]carbonyl]amino]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 696644-00-5 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[bis[4-(trifluoromethyl)phenyl]methyl]-2-(1,1-dimethylethyl)-, 1-[(1,1-dimethylethoxy)carbonyl]-4-piperidinyl ester, (2S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 696644-12-9 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[[(2S)-4-[bis[4-(trifluoromethyl)phenyl]methyl]-2-(1,1-dimethylethyl)-1-piperazinyl]carbonyl]ethylamino]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 696644-15-2 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[[(2S)-4-(diphenylmethyl)-2-(1-methylethyl)-1-piperazinyl]carbonyl]ethylamino]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 696644-40-3 CAPLUS

CN 1-Piperazinecarboxamide, N-(1-acetyl-4-piperidinyl)-2-(1,1-dimethylethyl)-4-[(S)-phenyl[4-(trifluoromethyl)phenyl]methyl]-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 696644-45-8 CAPLUS

CN 1-Piperazinecarboxamide, N-(1-acetyl-4-piperidinyl)-4-(diphenylmethyl)-2-(1-methylethyl)-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 696644-50-5 CAPLUS

CN 1-Piperazinecarboxamide, N-(1-acetyl-4-piperidiny)-4-[(4-chlorophenyl)phenylmethyl]-2-(1-methylethyl)-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 696644-54-9 CAPLUS

CN 1-Piperazinecarboxamide, N-(1-acetyl-4-piperidiny)-2-(1,1-dimethylethyl)-4-[phenyl[4-(trifluoromethyl)phenyl]methyl]-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 696644-58-3 CAPLUS

CN 1-Piperazinecarboxamide, N-(1-acetyl-4-piperidiny)-4-[bis[4-(trifluoromethyl)phenyl]methyl]-2-(1,1-dimethylethyl)-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 696644-60-7 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[bis[4-(trifluoromethyl)phenyl]methyl]-2-(1,1-dimethylethyl)-, 1-acetyl-4-piperidinyl ester, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 696644-64-1 CAPLUS

CN 1-Piperazinecarboxamide, N-(1-acetyl-4-piperidinyl)-4-(diphenylmethyl)-N-ethyl-2-(1-methylethyl)-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 696644-66-3 CAPLUS

CN 1-Piperazinecarboxamide, N-(1-acetyl-4-piperidinyl)-4-[bis[4-(trifluoromethyl)phenyl]methyl]-2-(1,1-dimethylethyl)-N-ethyl-, (2S)- (9CI) (CA INDEX NAME)

(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 696644-68-5 CAPLUS

CN 1-Piperazinecarboxamide, N-(1-acetyl-4-piperidinyl)-2-(1,1-dimethylethyl)-4-[phenyl[4-(trifluoromethoxy)phenyl]methyl]-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 696644-70-9 CAPLUS

CN 1-Piperazinecarboxamide, N-(1-acetyl-4-piperidinyl)-2-(1,1-dimethylethyl)-4-[4-(1,1-dimethylethyl)phenyl]phenylmethyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 696644-72-1 CAPLUS

# STN Columbus

CN 1-Piperazinecarboxamide, N-(1-acetyl-4-piperidinyl)-2-(1,1-dimethylethyl)-4-[(R)-phenyl[4-(trifluoromethyl)phenyl]methyl]-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 696644-78-7 CAPLUS

CN 1-Piperazinecarboxamide, N-(1-acetyl-4-piperidinyl)-2-(1,1-dimethylethyl)-4-[(S)-phenyl[4-(trifluoromethoxy)phenyl]methyl]-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 696644-82-3 CAPLUS

CN 1-Piperazinecarboxamide, N-(1-acetyl-4-piperidinyl)-2-(1,1-dimethylethyl)-4-[(R)-phenyl[4-(trifluoromethoxy)phenyl]methyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 696644-87-8 CAPLUS

# STN Columbus

CN 1-Piperazinecarboxamide, N-(1-acetyl-4-piperidiny1)-2-(1,1-dimethylethyl)-4-[(S)-[4-(1,1-dimethylethyl)phenyl]phenylmethyl]-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 696644-92-5 CAPLUS

CN 1-Piperazinecarboxamide, N-(1-acetyl-4-piperidiny1)-2-(1,1-dimethylethyl)-4-[(R)-[4-(1,1-dimethylethyl)phenyl]phenylmethyl]-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 696644-99-2 CAPLUS

CN 1-Piperazinecarboxamide, N-[2-(acetylamino)ethyl]-N-(1-acetyl-4-piperidiny1)-4-(diphenylmethyl)-2-(1-methylethyl)-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



=> file caold  
COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION

# STN Columbus

FULL ESTIMATED COST	5.39	172.52
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	-0.73	-0.73

FILE 'CAOLD' ENTERED AT 11:20:59 ON 02 OCT 2005  
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
 COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1907-1966  
 FILE LAST UPDATED: 01 May 1997 (19970501/UP)

This file contains CAS Registry Numbers for easy and accurate substance identification. Title keywords, authors, patent assignees, and patent information, e.g., patent numbers, are now searchable from 1907-1966. TIFF images of CA abstracts printed between 1907-1966 are available in the PAGE display formats.

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file supports REGISTRY for direct browsing and searching of all substance data from the REGISTRY file. Enter HELP FIRST for more information.

=> s 13  
 L5 0 L3

=>